Christina Christianson

Director, Biology and Translational Science

Role: Director, Biology and Translational Science at Ventyx Biosciences
Location: San Diego, CA, US
LinkedIn followers: 500 followers

About Christina Christianson

Experienced Scientist with a demonstrated history of designing and executing critical go/ no go experiments in the pharmaceuticals industry. PhD and post-doctoral training in innate and T-cell mediated diseases.

Experience

Director, Biology and Translational Science
Ventyx Biosciences
Jul 2022 — Present · San Diego, CA, US

Education

UC San Diego
Ph.D., Molecular Pathology
2006 — 2011
University of Rochester
BS, Biochemistry
2002 — 2006

Skills

Molecular Biology
Fluorescence Microscopy
Animal Surgery
Flow Cytometry
Small Animal Models
Rna Isolation
Microarray Analysis
Tissue Culture
Protein Assays
Transfection
Molecular Cloning
Animal Models
Primary Cell Isolation
Biochemistry
Immunohistochemistry
Qpcr
In Vivo
Dna Extraction
Tissue Processing

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
c••••••••@ventyxbio.com
Personal email
•••••@•••••.com
Direct dial
+18•••••••93

Unlock verified contacts

Free to start · No credit card required

Current company

Ventyx Biosciences

Biotechnology Research · 240 employees · San Diego, California, United States

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our deep expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.

ventyxbio.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.